HANSOH PHARMA(03692.HK): NDA for HS-10568 Injection Accepted by NMPA for Secondary Hyperparathyroidism in Dialysis Patients
NewTimeSpaceNews: Hansoh Pharmaceutical Group Company Limited (03692.HK) issued a voluntary announcement on June 10, 2026. The New Drug Application for its innovative drug HS-10568 Injection (partner code: SHR6508) was accepted by the National Medical Products Administration of China on June 9, 2026. The product is intended for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) receiving hemodialysis.
As an allosteric modulator of calcium-sensing receptor (CaSR), HS-10568 can enhance the receptor's sensitivity to extracellular calcium, thereby inhibiting the secretion of parathyroid hormone (PTH).
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Going Global Weekly: Pharma Out-Licensing Deals Land in Succession as the A-Share Hong Kong Listing Pipeline Expands-20261023
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- HANSOH PHARMA (03692.HK): Signs ADC Strategic Collaboration and Licence with Roche; US$400mn Upfront, Over US$15bn Milestones
- HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
- Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
